Ignite Creation Date:
2025-12-25 @ 3:32 AM
Ignite Modification Date:
2026-02-25 @ 11:03 PM
Study NCT ID:
NCT00168805
Status:
COMPLETED
Last Update Posted:
2014-05-19
First Post:
2005-09-12
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery
Sponsor:
Boehringer Ingelheim
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2004-11
Start Date Type:
None
Primary Completion Date:
2006-05
Primary Completion Date Type:
ACTUAL
Completion Date:
None
Completion Date Type:
None
First Submit Date:
2005-09-12
First Submit QC Date:
None
Study First Post Date:
2005-09-15
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2010-11-18
Results First Submit QC Date:
None
Results First Post Date:
2010-12-17
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2014-05-08
Last Update Post Date:
2014-05-19
Last Update Post Date Type:
ESTIMATED